Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Positron Emission Tomography01:29

Positron Emission Tomography

4.1K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.1K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

99
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
99

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glyco-Conjugation of Thiosemicarbazone Copper(II) Complexes Enhances Selectivity toward Cancer Cells Overexpressing GLUT1.

ACS omega·2026
Same author

<sup>68</sup>Ga radiolabeling strategies in Pt(IV)-deferoxamine scaffolds for potential theranostic application.

Dalton transactions (Cambridge, England : 2003)·2025
Same author

Evaluating methodological constraints in PET imaging of neuropeptide Y2 receptors with N-[<sup>11</sup>C]-methyl-(R)-JNJ-31020028 in brains of C57BL/6J mice.

EJNMMI radiopharmacy and chemistry·2025
Same author

Pt(IV) Prodrugs Bearing Sunitinib-Derived Ligands Display Exceptional Anticancer Activity against Renal Cell Carcinoma When Compared to Conventional Platinum Chemotherapy.

Journal of medicinal chemistry·2025
Same author

Assessing PET performance, image quality, and attenuation correction in the presence of RF coils within a 9.4 T MRI for preclinical simultaneous imaging.

EJNMMI physics·2025
Same author

Characterization of a Syngeneic Orthotopic Model of Cholangiocarcinoma by [<sup>18</sup>F]FDG-PET/MRI.

Cancers·2024

Related Experiment Video

Updated: Jun 17, 2025

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.8K

Recent Advances on Pt-Based Compounds for Theranostic Applications.

Giulia Ferrari1, Ines Lopez-Martinez2,3, Thomas Wanek3

  • 1Department of Chemistry, Maynooth University, W23 F2H6 Maynooth, Ireland.

Molecules (Basel, Switzerland)
|August 10, 2024
PubMed
Summary

Platinum-based drugs are advancing in cancer therapy through theranostic agents. These innovative systems combine platinum

Keywords:
cancer therapymolecular imagingplatinum chemotherapytheranostictherapy monitoring

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

1.3K

Related Experiment Videos

Last Updated: Jun 17, 2025

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.8K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

1.3K

Area of Science:

  • Oncology
  • Materials Science
  • Radiochemistry

Background:

  • Cisplatin and other platinum drugs are established anticancer agents, but face challenges in stability, efficacy, and side effects.
  • Theranostic approaches offer integrated diagnosis and therapy, enabling real-time monitoring and personalized treatment.
  • Platinum complexes are being developed as core therapeutic agents within sophisticated theranostic systems.

Purpose of the Study:

  • To review the role of platinum-based complexes in theranostic applications for cancer treatment.
  • To highlight recent advancements in integrating platinum complexes with diagnostic imaging modalities.
  • To discuss future perspectives in platinum-based theranostics.

Main Methods:

  • Review of literature on platinum-based theranostic agents.
  • Categorization of theranostic systems based on imaging techniques: fluorescence, PET, SPECT, and MRI.
  • Analysis of the integration of platinum therapeutic cores with diagnostic functionalized ligands.

Main Results:

  • Platinum complexes are effectively utilized as therapeutic agents in theranostic platforms.
  • Functionalized ligands enable diagnostic capabilities for tumor monitoring and treatment evaluation.
  • Advancements span across fluorescence, PET, SPECT, and MRI imaging integration.

Conclusions:

  • Platinum-based theranostic agents represent a significant advancement in personalized cancer therapy.
  • These systems offer simultaneous treatment and monitoring, improving therapeutic outcomes.
  • Continued research promises further innovation in platinum-based theranostics for oncology.